Standard BioTools Announces Operational Restructuring Plan to Drive Long-Term Profitable Growth
April 25, 2024 08:01 ET
|
Standard BioTools Inc.
Company expects to achieve $45-$50 million in annualized operating expense savings in fiscal 2025Management to discuss first quarter 2024 financial results, restructuring and strategic initiatives on...
Standard BioTools Announces Conference Call and Webcast for First Quarter 2024 Financial Results on May 8, 2024
April 25, 2024 08:00 ET
|
Standard BioTools Inc.
SOUTH SAN FRANCISCO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (“Standard BioTools” or the “Company”) (Nasdaq: LAB) today announced that it will report first quarter 2024...
Standard BioTools Introduces New High-Throughput Multiplexed Whole Slide Imaging Modalities Set to Redefine the boundaries of Tissue Imaging
April 08, 2024 08:00 ET
|
Standard BioTools Inc.
SOUTH SAN FRANCISCO, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health™ – today...
Standard BioTools Announces Multi-Year Strategic Engagement with Bristol Myers Squibb for Use of the SomaScan® Platform for Translational Medicine Research
April 03, 2024 16:01 ET
|
Standard BioTools Inc.
SOUTH SAN FRANCISCO, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health™ – today...
Standard BioTools Announces Exchange of All Outstanding Series B Convertible Preferred Stock for Common Stock
March 18, 2024 08:12 ET
|
Standard BioTools Inc.
SOUTH SAN FRANCISCO, Calif., March 18, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (“Standard BioTools” or the “Company”) (Nasdaq: LAB) today announced that it has exchanged all outstanding...
Standard BioTools Reports Fourth Quarter and Full Year 2023 Financial Results
February 28, 2024 16:01 ET
|
Standard BioTools Inc.
Achieved FY2023 core financial objectives, delivering substantial ongoing reductions in expenses and cash burn while expanding revenue and gross margins Completed merger with SomaLogic, activating...
Standard BioTools and Next Gen Diagnostics Announce Partnership to Provide Complete Automation of Low-Cost Pathogen Sequencing
February 26, 2024 08:00 ET
|
Standard BioTools Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health™ – and...
Standard BioTools to Participate in Upcoming Investor Conferences
February 22, 2024 16:05 ET
|
Standard BioTools Inc.
Standard BioTools to Participate in Upcoming Investor Conferences
Standard BioTools Announces Conference Call and Webcast for Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024
February 14, 2024 08:30 ET
|
Standard BioTools Inc.
Standard BioTools Announces Conference Call and Webcast for Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024
Standard BioTools and Navignostics Announce Collaboration Agreement to Advance Imaging Capabilities in Personalized Medicine
February 07, 2024 08:30 ET
|
Standard BioTools Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health™ – today...